Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Mol Cancer. 2024 Oct 1;23(1):219. doi: 10.1186/s12943-024-02139-z.

Authors

Claire Corcoran¹, Sweta Rani¹, Susan Breslin¹, Martina Gogarty¹, Irene M Ghobrial², John Crown³, Lorraine O'Driscoll⁴

Affiliations

¹ School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Oncology, St. Vincent's University Hospital, Dublin 4, Ireland.
⁴ School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland. lodrisc@tcd.ie.

No abstract available

Publication types

Editorial
Published Erratum
Expression of Concern

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Breast Neoplasms* / metabolism
Breast Neoplasms* / pathology
Disease Progression
Drug Resistance, Neoplasm / genetics
Female
Gene Expression Regulation, Neoplastic* / drug effects
Humans
MicroRNAs* / genetics
Receptor, ErbB-2* / genetics
Receptor, ErbB-2* / metabolism
Receptor, IGF Type 1* / genetics
Receptor, IGF Type 1* / metabolism

Substances

MicroRNAs
Receptor, ErbB-2
Receptor, IGF Type 1
IGF1R protein, human
ERBB2 protein, human
Antineoplastic Agents